Integer (ITGR) Expected to Announce Quarterly Earnings on Thursday

Integer (NYSE:ITGR) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $1.70 per share and revenue of $462.7250 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 9:00 AM ET.

Integer Stock Up 2.1%

ITGR stock opened at $87.69 on Wednesday. Integer has a one year low of $62.00 and a one year high of $144.76. The firm has a market cap of $3.07 billion, a PE ratio of 36.69, a PEG ratio of 0.79 and a beta of 0.77. The firm’s 50 day moving average price is $82.08 and its 200-day moving average price is $88.46. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.45 and a current ratio of 3.71.

Integer announced that its board has initiated a stock repurchase program on Tuesday, November 4th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to buy up to 8.3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen lowered Integer from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. Truist Financial boosted their price objective on shares of Integer from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Raymond James Financial reaffirmed an “outperform” rating and set a $95.00 target price (down previously from $143.00) on shares of Integer in a research note on Friday, October 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Integer in a research note on Monday, December 29th. Finally, Piper Sandler decreased their price objective on shares of Integer from $155.00 to $82.00 and set an “overweight” rating on the stock in a report on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Integer has an average rating of “Hold” and an average price target of $98.38.

Institutional Investors Weigh In On Integer

Large investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust boosted its position in Integer by 135.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 267 shares during the period. Arax Advisory Partners raised its stake in shares of Integer by 2,489.5% in the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 473 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Integer by 210.5% in the second quarter. EverSource Wealth Advisors LLC now owns 534 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 362 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Integer by 861.1% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 692 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 620 shares in the last quarter. Finally, State of Wyoming increased its holdings in Integer by 434.2% during the 4th quarter. State of Wyoming now owns 1,608 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 1,307 shares during the period. 99.29% of the stock is owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.